Other
Sacituzumab Tirumotecan
0
Pipeline Programs↗
6
Active Trials↗
1
Companies Involved↗
Sacituzumab Tirumotecan is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Not yet recruiting3 · 50%
Recruiting2 · 33%
Active, not recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07088211·39 enrolled
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
Not yet recruiting·—·Phase 2·NCT07388875·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)